The Food and Drug Administration (FDA) has expanded the approval of Simponi ® (golimumab) to include pediatric patients weighing at least 15kg with moderate to severely active ulcerative colitis (UC).

Led by researchers at MD Anderson Cancer Center, the study demonstrated an overall objective response rate of 25% (n=4) among patients with ...

The company expects top-line results in 2026 from this group of the basket trial testing the drug plixorafenib as a ...

Can Pfizer’s GDF15-blocking, appetite-boosting antibody ponsegromab address a cancer-induced wasting syndrome — and help ...

Results published in Oxford Academic’s Military Medicine Journal -- After up to 18 months of follow-up patients were observed to have zero ...